Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc. (MTNB)
Filing Type: Form 8-K (Current Report)
Report Date: March 27, 2024
Reporting Period: This filing announces financial results for the year and quarter ended December 31, 2023. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data. It references a press release (Exhibit 99.1) for the actual figures. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not provide specific data to compare against prior periods. It serves only to notify investors that results for the period ended December 31, 2023, have been issued.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the Company issued a press release on March 27, 2024, regarding its financial results. The full text of this commentary is incorporated by reference in Exhibit 99.1.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that Section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 27, 2024) for actual revenue, net loss, and cash position figures.
- Verify the specific details of the "Results of Operations" which are referenced but not detailed in this 8-K cover sheet.
- Check the Company's website or investor relations portal for the full text of the press release to assess year-over-year performance.